Executive Summary
This deep-dive covers healthspan therapeutics, specifically the NAD+ precursor arm exemplified by nicotinamide riboside (NR) and its commercial lead product, Niagen/Tru Niagen from ChromaDex. The evidence base includes a granted US patent, multiple peer-reviewed papers, an FDA technical guidance document, and SEC EDGAR filings. The core finding is that NR has a legally recorded composition/use patent and reproducible human evidence for raising NAD+ biomarkers, but the step from “NAD+ elevation” to “proven human healthspan extension” is not established by the strongest available evidence. A granted patent is evidence of recorded claims, not clinical performance.
A worked allometric calculation shows that the mouse dose most commonly used in a foundational NR metabolism study (400 mg/kg/day) would translate to roughly 2.3 g/day in a 70 kg adult under FDA conversion assumptions—well above typical consumer supplement doses but within the range of published human single-dose studies.
Scope and source map
The source tiers used here are:
| Tier | Source type | Used here |
|---|---|---|
| Tier 1 | Granted patents, peer-reviewed papers, regulator technical documents | US 8,106,184 B2; Canto 2012; Martens 2018; Trammell 2016; FDA 2005 guidance |
| Tier 2 | Company SEC filings, corporate disclosure | ChromaDex 10-K EDGAR index; other ticker SEC EDGAR indexes |
| Prohibited | SEO content farms, AI summaries, anonymous benchmarks | Not used |
I did not use a company technical blog as a load-bearing technical source. SEC filings are used for adoption/commercial context, not to prove that NR extends lifespan.
The technology: NAD+ precursors as healthspan interventions
The mechanistic hypothesis runs as follows: NAD+ is a coenzyme required for oxidation-reduction reactions, sirtuin function, and DNA repair. NAD+ levels decline in multiple tissues with age. Restoring NAD+ by supplying a precursor—nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN)—is therefore proposed as a healthspan intervention.
This is not merely a consumer wellness claim. Peer-reviewed work has demonstrated that NR is orally bioavailable and raises NAD+ metabolism in both mice and humans.
Citation-bound language:
- NR is a pyridine-nucleoside vitamin B3 metabolite and NAD+ precursor [S1].
- In mice, NR supplementation improved oxidative metabolism and protected against high-fat-diet-induced obesity at a reported dose of 400 mg/kg/day [S2].
- In a human Phase 1 randomized trial, oral NR was well tolerated and raised NAD+ levels in healthy middle-aged and older adults [S3].
- In a separate human pharmacokinetic study, NR was orally bioavailable and increased NAD+ metabolism in humans [S4].
Load-bearing claim cross-verification:
- “NR raises NAD+ biomarkers in humans” is supported by two independent human studies from different institutions: Martens et al. 2018 [S3] and Trammell et al. 2016 [S4]. This cross-verification is independent at the institutional level and supports feasibility of NAD+ elevation.
- “NR improves metabolic endpoints in mice” is currently [SINGLE-SOURCE] for the high-fat-diet mouse paper [S2]. That claim should be treated as provisional until replicated in an independent mouse study from another group.
The granted patent: US 8,106,184 B2
The strongest Tier 1 intellectual-property document identified here is:
- US Patent 8,106,184 B2, “Nicotinoyl riboside compositions and methods of use,” assigned to Cornell Research Foundation, Inc., granted 2012-01-31 [S1].
- URL:
https://patents.google.com/patent/US8106184B2/en - Access date: 2026-04-25.
This is a granted patent, not an application. That distinction matters. The patent is admissible as Tier 1 for recorded claims, but it is not proof that NR works in humans. A patent examiner does not require Phase 3 efficacy data. In this analysis, the patent supports the moat/legal-exclusivity question, not the clinical-performance question.
For exact claim language, see the linked patent text. The patent family is commercially relevant because ChromaDex has represented in SEC filings that it commercializes NR through rights to Cornell patents [S6].
Peer-reviewed evidence
4.1 Foundational mouse paper — Canto 2012
- Canto C, et al. “The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.” Cell Metabolism 15(6):838–847, 2012. DOI:
10.1016/j.cmet.2012.04.022[S2]. - Published: 2012-06-06? The DOI resolves to Cell Metabolism; publication year 2012. Access date: 2026-04-25.
The paper reports that NR at 400 mg/kg/day protected against diet-induced metabolic dysfunction in mice [S2]. This is a peer-reviewed journal article, not a preprint. It is the strongest Tier 1 animal-efficacy source used here.
Tag: The specific dose-response and metabolic-outcome claim from this paper is [SINGLE-SOURCE] unless a second independent mouse study is retrieved.
4.2 Human Phase 1 trial — Martens 2018
- Martens CR, et al. “Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.” Nature Communications 9, Article 1286 (2018). DOI:
10.1038/s41467-018-03421-7[S3]. - Published: 2018-03-29. Access date: 2026-04-25.
This is the strongest human safety/tolerability and NAD+ biomarker paper cited here. It is a peer-reviewed human randomized trial, not a preprint. The trial reported that oral NR elevated NAD+ biomarkers, but the same publication did not establish a clinical hard endpoint of lifespan or healthspan extension in humans [S3]. This is a key source for the contradiction section below.
4.3 Human pharmacokinetic paper — Trammell 2016
- Trammell SA, et al. “Nicotinamide riboside is uniquely and orally bioavailable in mice and humans.” Nature Communications 7, 12948 (2016). DOI:
10.1038/ncomms12948[S4]. - Published: 2016. Access date: 2026-04-25.
This paper provides a second human-dosed study showing NR increases NAD+ metabolites [S4]. Because it comes from a different research group than Martens 2018, it cross-verifies the human oral bioavailability claim.
Company filing cross-reference and marketing-vs-disclosure gap
ChromaDex Corporation is the public company most directly tied to NR. Its SEC EDGAR filing index is:
- SEC EDGAR, ChromaDex Corp., Form 10-K filing index, CIK/ticker CDXC [S6]:
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&ticker=CDXC&type=10-K&dateb=&owner=include&count=40
- Access date: 2026-04-25.
Observed gap: Consumer-facing marketing for Niagen/Tru Niagen often uses statements such as “clinically proven to increase NAD+.” The peer-reviewed human evidence [S3][S4] supports NAD+ biomarker elevation, but the SEC filing risk disclosures describe a dietary-supplement business with legal, competitive, and regulatory risk [S6]. SEC filings do not, in the retrieved index, constitute an FDA therapeutic approval for an anti-aging indication. The accurate synthesis is: marketing claims are biomarker-level; the filed business risk is product-level; no FDA therapeutic approval for NR as a drug is established in the sources used.
No specific revenue, gross margin, or royalty rate is asserted here because those numbers were not retrieved from the underlying 10-K text. They should be marked needs primary source validation until the exact 10-K accession number and line items are retrieved.
Worked quantitative calculation: mouse-to-human allometric dose conversion
A load-bearing question in this therapeutic area is whether the mouse doses used in efficacy studies are relevant to human supplementation. The FDA provides an allometric conversion using body surface area.
Formula:
\[
\text{HED (mg/kg)} = \text{animal dose (mg/kg)} \times \left(\frac{\text{animal }K_m}{\text{human }K_m}\right)
\]
Where:
- \(K_m\) for mouse = 3 mg/kg per m²²? The FDA convention is 3 for mouse and 37 for human [S5].
- Animal dose from Canto 2012 = 400 mg/kg/day [S2].
Inputs:
\[
\text{HED} = 400 \times \left(\frac{3}{37}\right) = 400 \times 0.0811 = 32.4 \text{ mg/kg/day}
\]
For a 70 kg adult:
\[
32.4 \times 70 = 2,268 \text{ mg/day}
\]
Sensitivity table:
| Mouse dose assumption | Human equivalent dose (70 kg) |
|---|---|
| 100 mg/kg/day | \(100 \times 0.0811 \times 70 = 567 \text{ mg/day}\) |
| 400 mg/kg/day | \(400 \times 0.0811 \times 70 = 2,268 \text{ mg/day}\) |
| 500 mg/kg/day | \(500 \times 0.0811 \times 70 = 2,835 \text{ mg/day}\) |
Interpretation with source-bound caveats: The 2.3 g/day human-equivalent calculation is an estimated starting-dose conversion, not a recommendation and not proof that 2.3 g/day is safe or effective. The FDA guidance itself states that animal-to-human dose conversion is only one part of a safety assessment [S5]. This calculation does not override the human trial data showing that smaller doses also raise NAD+ biomarkers [S3][S4].
Parameter table
| Parameter | Value | Source (URL + ID + date) | Tier | Measured/derived/assumed/inferred | Cross-verified |
|---|---|---|---|---|---|
| Mouse NR dose in Canto 2012 | 400 mg/kg/day | S2, DOI 10.1016/j.cmet.2012.04.022, 2012 | Tier 1 peer-reviewed | Measured/reported | No — single-source |
| Mouse \(K_m\) | 3 | S5, FDA guidance, 2005 | Tier 1 regulator | Standard | Yes — FDA standard |
| Human \(K_m\) | 37 | S5, FDA guidance, 2005 | Tier 1 regulator | Standard | Yes — FDA standard |
| HED for 400 mg/kg mouse dose | 32.4 mg/kg/day | Calculated above | — | Derived | No |
| 70 kg adult HED | 2,268 mg/day | Calculated above | — | Derived | No |
| Human NR dose studied | 1,000 mg/day | S3, DOI 10.1038/s41467-018-03421-7, 2018 | Tier 1 peer-reviewed | Measured/reported | Yes — S4 |
| Human NAD+ biomarker elevation | Significant after oral NR | S3 and S4, DOIs above | Tier 1 peer-reviewed | Measured | Yes — two independent studies |
| NR patent grant date | 2012-01-31 | S1, US8106184B2 | Tier 1 patent | Recorded legal event | Yes — patent record |
Contradictions and source-bound caveats
- Mouse efficacy vs human efficacy gap. The mouse paper reports metabolic protection [S2]; the human Phase 1 paper reports NAD+ biomarker elevation but does not establish a clinical hard endpoint [S3]. These are not equivalent claims. The strongest supported statement is: NR raises NAD+ in humans; it is not proven from these sources to extend human healthspan or lifespan.
- Patent strength vs performance. US 8,106,184 B2 is a granted patent and is Tier 1 for recorded legal claims [S1]. It is not performance evidence. A patent can be valid and commercially valuable even if the underlying product has not demonstrated therapeutic efficacy.
- Dose translation contradiction. The mouse efficacy dose converts to a daily human dose above many consumer supplement label amounts. Human biomarker effects were observed at 1,000 mg/day [S3], lower than the allometric estimate but still within the same order of magnitude. This creates a tension between “dose used in animal efficacy” and “dose used in human studies,” and it should be resolved with formal PK/PD work rather than marketing language.
- Marketing vs SEC filed-business reality. Marketing emphasizes “clinically proven” NAD+ elevation [S3][S4]. The SEC 10-K index for CDXC is a disclosure of a dietary-supplement/ingredient business with litigation and regulatory risk [S6]. These are different evidentiary registers.
Unit economics / business model
Who monetizes this technology:
- ChromaDex Corporation (CDXC) sells NR as an ingredient and as a branded consumer product. SEC EDGAR filing index identifies it as the public company associated with the NR commercialization [S6].
- Cornell Research Foundation assigned the exemplified granted patent to Cornell, which is a legal owner/assignee for licensing [S1].
How it is monetized:
- Bulk NR ingredient sales to supplement/consumer-product companies.
- Branded direct-to-consumer finished products.
- Potential patent licensing/royalty economics from the Cornell patent family [S1][S6].
Margins: This note does not assert a specific gross margin, contribution margin, or royalty rate. Those figures require retrieval of the full 10-K or license agreement; they are needs primary source validation.
Who captures value: The value appears split between the patent owner/licensor and the branded seller. In the CDXC case, the public company captures value through its branded business and ingredient sales; the university licensor captures licensing value [S1][S6]. The consumer ultimately pays a retail price that includes brand margin, but that retail margin is not independently verified here.
Disconfirming Evidence
The NAD+ precursor healthspan thesis would be materially weakened by any of the following, if verified in primary sources:
- A randomized Phase 3 or large controlled trial showing no significant improvement in a prespecified healthspan endpoint—frailty, physical function, cardiovascular events, or all-cause mortality—after NR supplementation.
- A US court or patent-office final decision invalidating or narrowing US 8,106,184 B2 or removing ChromaDex’s exclusive rights to the Cornell NR patent family [S1].
- A regulatory action determining that NR-containing products are misbranded or that NAD+ precursor claims are not acceptable for dietary supplements.
- Independent replication failure of the human NAD+ elevation result. The current evidence is cross-verified by Martens 2018 and Trammell 2016 [S3][S4], but a larger study with no NAD+ increase would contradict this base finding.
- Competitive establishment of a cheaper or more bioavailable NAD+ precursor with similar or better safety, reducing the NR-specific moat.